Study guide

Cardiovascular & Renal Drugs PNLE Questions

Pharmacology· 28 published questions ·Question inventory updated August 12, 2026
Cardiovascular & Renal Drugs PNLE Questions
Cognitive level
Where these questions land on Bloom's taxonomy.
L1 Remembering
25%
L2 Understanding
11%
L3 Applying
46%
L4 Analyzing
11%
L5 Evaluating
7%
L6 Creating
0%
Topic distribution
Common themes across 28 questions in this area.
Pharmacology
48
Mental Health
40
Patient Safety
35
Cardiac Disorders
35
Assessment
23
Pain Management
9
Fundamentals of Nursing
9
Vital Signs
8
Geriatric Nursing
8
Community Health
5
Public Health
5

Introduction

Exactly 35 original PNLE-style practice questions are currently published for Cardiovascular & Renal Drugs. The inventory was last updated August 12, 2026. Use this set to practice safe medication decisions, not to infer a guaranteed number of questions on a future exam.

The canonical scope covers antihypertensive, antianginal, heart-failure, antiarrhythmic, diuretic, and renal medications. Questions in this lens help you connect a drug or class with its purpose, expected response, adverse cue, assessment priority, monitoring need, or next nursing action. Anticoagulants and blood-forming medications belong in Hematologic Drugs.

Tangerine places this topic under NP7: Pharmacology, while the official 2025 Enhanced TOS maps the lens across relevant competencies in the official five-subject PNLE TOS. It is not a separate official test subject, and the TOS does not assign a guaranteed microtopic weight. Exact microtopic distribution varies by exam form.

Key concepts

  • Match the medication to the physiologic goal
    Recognize: Antihypertensives lower pressure or reduce workload; antianginals improve myocardial oxygen balance; heart-failure and diuretic drugs address workload or excess fluid; antiarrhythmics target rhythm; renal medications may require kidney-based monitoring.
    Decide: Name the intended physiologic goal before judging whether an assessment finding is therapeutic or concerning.
    Avoid: Treating every cardiovascular drug as interchangeable or choosing an answer from the medication name alone.
  • Prioritize perfusion after pressure-lowering therapy
    Recognize: Hypotension, marked dizziness, weakness, syncope, or new poor perfusion after an antihypertensive or sublingual nitroglycerin dose.
    Decide: Protect the patient from injury, assess blood pressure and perfusion, and escalate according to the clinical situation, orders, and local protocol.
    Avoid: Repeating a dose or labeling symptoms routine before assessing the patient.
  • Connect heart-failure findings with fluid and organ status
    Recognize: New dyspnea, increasing edema, reduced urine output, or worsening fatigue may signal a change in heart-failure or fluid status.
    Decide: Assess respiratory status, perfusion, fluid balance, urine output, renal status, and prescribed monitoring before concluding that treatment is effective.
    Avoid: Assuming that any change is a simple expected diuretic effect or waiting for severe deterioration before reporting it.
  • Link potassium-retaining therapy with renal decline
    Recognize: Spironolactone-related hyperkalemia risk becomes more concerning when renal function declines. Weakness, paresthesia, or rhythm changes require prompt attention.
    Decide: Review available potassium and renal results, assess the patient, and escalate concerning findings while following the prescribed plan.
    Avoid: Assuming urine output alone proves electrolyte safety or independently changing treatment without an order or protocol.
  • Assess rhythm drugs through stability cues
    Recognize: Rhythm, pulse, blood pressure, mental status, chest discomfort, and dyspnea must be interpreted together during antiarrhythmic therapy.
    Decide: Determine whether the patient is stable while monitoring the rhythm and escalating signs of impaired perfusion or acute deterioration.
    Avoid: Selecting an antiarrhythmic response solely because the heart rate is fast or slow.
  • Keep medication-domain boundaries clear
    Recognize: This page centers on six named groups: antihypertensive, antianginal, heart-failure, antiarrhythmic, diuretic, and renal medications. Anticoagulants and blood-forming medications are assigned to Hematologic Drugs.
    Decide: Identify the medication domain first, then apply the relevant monitoring and safety principle.
    Avoid: Letting a familiar cardiovascular presentation pull the rationale into an excluded medication category.

What to expect on the PNLE

The 35-question inventory supports question forms that ask for an expected medication effect, an adverse or worsening cue, a priority nursing response, a monitoring concern, or the role of a drug during an urgent cardiovascular situation. Representative scope evidence also supports decisions involving nitroglycerin-related hypotension, heart-failure symptom changes, diuretic safety, spironolactone with renal decline, and antiarrhythmic or arrest medication roles.

The live difficulty distribution is easy 6, medium 24, and hard 5. The live Bloom distribution is remembering 11, understanding 5, applying 14, analyzing 3, and evaluating 2. This profile supports strong retrieval of drug purposes and safety facts, with particular practice in applying a clinical cue to the correct nursing action. Exact topic distribution varies by exam form.

  • Remembering: Retrieve medication purposes, class associations, and key monitoring concerns.
  • Understanding: Explain why a finding reflects therapeutic response, adverse effect, or worsening disease.
  • Applying: Use blood pressure, rhythm, fluid, renal, and electrolyte cues to select the safest action.
  • Analyzing and evaluating: Prioritize competing findings, distinguish stable from unstable presentations, and judge which option best protects perfusion and medication safety.

Study tips

  1. Start with diagnostic practice. Answer a short mixed set drawn from the 35 published questions without opening notes. Mark whether each miss came from drug purpose, assessment, adverse effect, prioritization, or scope confusion.
  2. Use focused retrieval by drug group. For each class, recall the main physiologic goal, the first assessment, the important monitoring concern, the dangerous cue, and the nursing action. Say the reasoning aloud before checking the answer.
  3. Make a comparison grid. Draw five columns and complete one row for each class: Class | Main goal | First assessment | Danger cue | Nursing response.
    Example diagram to complete:
    Antihypertensive | ____ | ____ | ____ | ____
    Antianginal | ____ | ____ | ____ | ____
    Heart-failure or diuretic | ____ | ____ | ____ | ____
    Antiarrhythmic | ____ | ____ | ____ | ____
    Renal medication | ____ | ____ | ____ | ____
  4. Review the rationale and the error. For every missed or guessed item, write the clinical cue, the safety risk, and the action that follows. Record why each distractor is less safe rather than copying only the correct letter.
  5. Retry with spacing, then mix. Reattempt missed concepts after a gap, using new wording and a different drug group when possible. Once focused retrieval is reliable, complete mixed timed practice that combines all six groups and requires both recall and clinical decision-making.

Common mistakes to avoid

  • Calling post-dose dizziness automatically expected. A learner may remember that pressure-lowering drugs can cause dizziness and stop reasoning. The correcting cue is the patient’s blood pressure, perfusion, severity of symptoms, and injury risk; assess first and escalate when findings are concerning.
  • Judging heart-failure therapy from one symptom. Improved urine output does not by itself establish safe or effective treatment. Compare respiratory status, edema, fluid balance, urine output, perfusion, renal status, and ordered monitoring.
  • Missing the spironolactone and renal-decline connection. Focusing only on fluid removal can hide potassium risk. Renal decline increases concern for hyperkalemia, so review relevant results and assess for weakness or rhythm changes.
  • Choosing an antiarrhythmic by rate alone. A fast or slow pulse is incomplete information. Rhythm, blood pressure, mental status, chest discomfort, dyspnea, and perfusion determine urgency and the safest next action.
  • Mixing medication domains. Cardiovascular symptoms can appear in questions about anticoagulants or blood-forming medications, but those belong to Hematologic Drugs. Identify the drug category before applying a rationale so the monitoring principle matches the scope.

More Cardiovascular & Renal Drugs questions

Question 2 Medium

A hospitalized patient with suspected acute coronary syndrome receives one prescribed sublingual nitroglycerin dose. Five minutes later, chest pain persists, the patient is dizzy, and blood pressure is 86/54 mmHg. What should the nurse do next?

A.

Withhold the next dose, keep the patient supine, and reassess in fifteen minutes before reporting

B.

Withhold the next dose, continue prescribed maintenance fluids, and document the response before reporting

C.

Withhold the next dose and wait to see whether the dizziness resolves before contacting the prescriber

D.

Withhold another nitroglycerin dose, maintain monitoring, and immediately report the symptomatic hypotension

Question 3 Hard

Pulseless VT persists after two shocks. CPR has resumed, IV access is ready, and no drug has been given. Which sequence best follows the shockable-arrest algorithm if the rhythm remains shockable?

A.

Give epinephrine during CPR; shock after the rhythm check; then administer amiodarone only after the subsequent rhythm check.

B.

Give epinephrine during CPR; shock after the rhythm check; then give amiodarone or lidocaine during CPR

C.

Shock after the rhythm check; give amiodarone during CPR, then administer epinephrine during the next CPR cycle

D.

Give amiodarone during CPR; shock after the rhythm check; then defer epinephrine until another cycle

Question 4 Hard

Ascites improves on spironolactone, but potassium rises from 4.7 to 5.8 mmol/L and eGFR falls. Which response best balances benefit and harm?

A.

Reduce spironolactone by half, arrange prompt renal and potassium reassessment, and continue monitoring ascites response.

B.

Hold spironolactone, assess ECG risk and interacting drugs, repeat urgent laboratories, and revise the diuretic plan

C.

Replace spironolactone with eplerenone today, then monitor potassium and renal function closely during titration.

D.

Continue the current dose, stop interacting potassium-raising drugs, and repeat potassium and renal tests later today

References and further reading

How this page is built

The counts and distributions on this page come from Tangerine Prep's live published question bank. The source inventory was last updated on August 12, 2026.

The questions are original PNLE-style practice items, not recalled or leaked board questions. Topic scope follows Tangerine's pedagogical taxonomy and is mapped to the PRC 2025 Enhanced Table of Specifications, effective from the November 2025 NLE onward. Exact topic distribution varies by exam form.